Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2017 on request of the Sponsor.
On 21 June 2004, orphan designation (EU/3/04/203) was granted by the European Commission to PPD Global Ltd, United Kingdom, for 5'CTG CCA CGT TCT CCT GC (2' methoxy)A (2' methoxy)C-(2'methoxy)C-3' for the treatment of myasthenia gravis.
5'-CTG CCA CGT TCT CCT GC-(2' methoxy)A-(2' methoxy)C-(2' methoxy)C-3'
|Disease / condition||
Treatment of myasthenia gravis
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: